A Phase 4 interventional study of Clopidogrel & Aspirin, Prasugrel & Aspirin and Placebo & Aspirin in Coronary Artery Disease, sponsored by Cordis Corporation. Status unknown at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-02-07.
Sponsored by Cordis Corporation · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies testing clopidogrel in Coronary Artery Disease — 3 open to participants now, 3 under way, 1 of them phase 3. Clopidogrel · Coronary Artery Disease.
Among the 71 studies testing clopidogrel in Coronary Artery Disease, this one is the 10th largest by enrollment, is one of 8 that started in 2009, is one of 53 in phase 4, and was the 24th registered.
4,863 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →3 of the 71 studies testing clopidogrel in Coronary Artery Disease are open now, in 3 countries. Recruiting first, the newest first:
University of Florida · Sites in United States
Ages 18+
China National Center for Cardiovascular Diseases · Sites in China
Ages 18–75
St. Antonius Hospital · Sites in Netherlands
Ages 18+
By country, each count listing its studies:
Clopidogrel: first FDA approval 1997 (PLAVIX), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 8 · Phase 4 53
First in 2004; this study’s year is marked. 8 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,509 is above the median of 124 across 3,010 interventional studies indexed under Coronary Artery Disease.
Median enrollment 120 across the 71 interventional studies. Of the 57 that completed or were terminated, 15 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 71 have an industry lead sponsor. The 10 most frequent:
Cordis Corporation is the lead sponsor of 70 studies on the registry; none are open to participants now.
41 studies in Coronary Artery Disease by Cordis Corporation: none open now, none under way, none of them phase 3. Of 39 finished, 3 (8%) have results posted.
Among the 41 studies in Coronary Artery Disease by Cordis Corporation, this one is the 3rd largest by enrollment of the 39 interventional ones that give a count, is the only one that started in 2009, is one of 12 in phase 4, and was the 38th registered.
Cordis Corporation’s Coronary Artery Disease studies by the year they started, since 1999.
2 of the studies testing clopidogrel in Coronary Artery Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05638867China National Center for Cardiovascular DiseasesNOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI | 2026-12 |
| NCT07025148University of FloridaDual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2) | 2027-08-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 71 studies testing clopidogrel in Coronary Artery Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Cordis Corporation’s 41 in Coronary Artery Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
CYPRESS: A Prospective,Randomized,Multi-Center,Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention with the CYPHER® Sirolimus-eluting Coronary Stent (CYPHER® Stent)
During Phase I (non-randomized phase) of this study, the primary objective is to assess the rate of target lesion failure in subjects implanted with the CYPHER® stent and receiving dual antiplatelet therapy for 12 months.
During Phase II (randomized phase) of this study, the primary objective is to assess safety (major and minor bleeding), MACCE, and ST rates in subjects treated with dual antiplatelet therapy for 12 or 30 months following CYPHER® stent implantation.
*Subjects treated with the CYPHER® 2.25mm stent will be followed through 60 months.
**The last 500 patients enrolled will not be eligible for randomization.
DAPT Group - Inclusion Criteria:
Phase I: Enrollment Inclusion Criteria
Subjects must meet ALL of the following inclusion criteria to be enrolled in the study:
DAPT Group Phase II: Randomization Inclusion Criterion at 12 months
Subjects must meet the following criterion to be eligible for randomization in the study:
DAPT Group - Exclusion Criteria:
Phase I: Enrollment Exclusion Criteria
Subjects will be excluded if ANY of the following exclusion criteria apply:
DAPT Group Phase II: Randomization Exclusion Criteria at 12 months
Subjects will be excluded from randomization if any of the following criteria are met:
Non-DAPT Group
The following inclusion and exclusion criteria are for the Non-DAPT subjects. These criteria will be used to determine if the subject meets the near on-label definition
Non-DAPT Group - Inclusion Criteria:
Subjects must meet ALL of the following criteria to be enrolled in this study:
Non-DAPT Group - Exclusion criteria
And must NOT meet any of the following exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo & Aspirin
Drug: Clopidogrel & Aspirin, Prasugrel & Aspirin
Drug pages: Clopidogrel · Aspirin · Prasugrel
This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of thienopyridine treatment in addition to aspirin.
This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.
Phase I: the Rate of Target Lesion Failure (TLF)
Target lesion failure (TLF) is defined as clinically-driven target lesion revascularization, target vessel myocardial infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vessel at 12 months.
Time frame: 12 months
Rate of Device Success
A study device success is defined as achievement of a final residual diameter stenosis of \< 50% (by QCA), using the assigned device only. If QCA is not available, the visual estimate of diameter stenosis is used.
Time frame: From post- procedure to hospital discharge, up to 39 days
Rate of Lesion Success
Lesion success is defined as the attainment of \< 50% residual stenosis (by Quantitative coronary angiography (QCA)) using any percutaneous method.
Time frame: From post- procedure to hospital discharge, up to 39 days
Rate of Procedure Success
Procedure success is defined as the achievement of a final diameter stenosis of \< 50% (by QCA) using any percutaneous method, without the occurrence of death, Myocardial infarction (MI), or repeat coronary revascularization of the target lesion during the hospital stay.
Time frame: From post- procedure to hospital discharge, up to 39 days
Rate of Clinically-driven Target Lesion Revascularization (TVR)
Defined as any "clinically-driven" repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel. Clinically-driven revascularizations are those in which the subject has a positive functional study, ischemic ECG changes at rest in a distribution consistent with the target vessel, or ischemic symptoms, and an in-lesion diameter stenosis ≥50% by QCA.
Time frame: 12 Months
Rate of Clinically Driven Target Vessel Revascularization (TVR)
Defined as any clinically driven repeat percutaneous intervention of the target vessel or bypass surgery of the target vessel. Clinically-driven revascularizations are those in which the subject has a positive functional study, ischemic ECG changes at rest in a distribution consistent with the target vessel, or ischemic symptoms, and an in-lesion diameter stenosis ≥50% by QCA.
Time frame: 12 months
Rate of Target Vessel Failure (TVF)
Defined as target vessel revascularization, recurrent infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vessel.
Time frame: 12 Months
Rate of Major Adverse Cardiac Events (MACE)
MACE includes Death, myocardial infarction, emergent bypass surgery, or target lesion revascularization at 12 months
Time frame: 12 Months
Rate of Protocol Defined Stent Thrombosis (ST)
Protocol defined ST includes early and late ST. Early thrombosis is defined as composite thirty-day ischemic endpoint including death, Q-wave myocardial infarction, or subabrupt closure requiring revascularization. Late thrombosis is defined as myocardial infarction occurring \> 30 days after the index procedure and attributable to the target vessel with angiographic documentation (site reported or by qualitative coronary angiography) of thrombus or total occlusion at the target site and freedom from an interim revascularization of the target vessel.
Time frame: 12 Months
Rate of Academic Research Consortium (ARC) Defined Stent Thrombosis (ST)
ARC defined ST classifies ST by type - definite, probable, possible; by timing - acute, sub-acute, late, very late. Definite includes angiographic or pathologic confirmation; probable includes Any unexplained death within the first 30 days or Any MI (related to documented acute ischemia and without another obvious cause) in the territory of the stent; Possible includes Any unexplained death \> 30 days. Acute includes those ≤ 24 hours post procedure; sub-acute includes those \> 24 hours to ≤ 30 days post procedure; and late includes those \> 30 days to ≤ 1 year post procedure; and very late includes those \> 1 year post procedure.
Time frame: 12 Months
Rate of Protocol Defined Major Bleeding Complications
Defined by the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) classification, including severe and moderate bleeding combined.
Time frame: 12 Months
Rate of Cardiac Death
Include all deaths due to cardiac causes.
Time frame: 12 Months
Rate of Non-cardiac Death
Include all deaths due to non-cardiac causes.
Time frame: 12 Months
A total of 2509 patients were enrolled from August 28, 2009 to January 14, 2011 across 139 clinical sites in the Unites States.
| Milestone | All Enrolled Subjects |
|---|---|
| Started | 2509 |
| Completed | 2342 |
| Not completed | 167 |
| Withdrew: Death | 34 |
| Withdrew: Withdrawal by subject | 100 |
| Withdrew: Lost to follow-up | 33 |
Target lesion failure (TLF) is defined as clinically-driven target lesion revascularization, target vessel myocardial infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vessel at 12 months.
| participants | CYPHER® Stent |
|---|---|
| Phase I: the Rate of Target Lesion Failure (TLF) | 149 |
A study device success is defined as achievement of a final residual diameter stenosis of \< 50% (by QCA), using the assigned device only. If QCA is not available, the visual estimate of diameter stenosis is used.
| Devices | CYPHER® Stent |
|---|---|
| Rate of Device Success | 3205 |
Lesion success is defined as the attainment of \< 50% residual stenosis (by Quantitative coronary angiography (QCA)) using any percutaneous method.
| Lesions | CYPHER® Stent |
|---|---|
| Rate of Lesion Success | 3264 |
Procedure success is defined as the achievement of a final diameter stenosis of \< 50% (by QCA) using any percutaneous method, without the occurrence of death, Myocardial infarction (MI), or repeat coronary revascularization of the target lesion during the hospital stay.
| participants | CYPHER® Stent |
|---|---|
| Rate of Procedure Success | 2444 |
Defined as any "clinically-driven" repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel. Clinically-driven revascularizations are those in which the subject has a positive functional study, ischemic ECG changes at rest in a distribution consistent with the target vessel, or ischemic symptoms, and an in-lesion diameter stenosis ≥50% by QCA.
| participants | CYPHER® Stent |
|---|---|
| Rate of Clinically-driven Target Lesion Revascularization (TVR) | 98 |
Defined as any clinically driven repeat percutaneous intervention of the target vessel or bypass surgery of the target vessel. Clinically-driven revascularizations are those in which the subject has a positive functional study, ischemic ECG changes at rest in a distribution consistent with the target vessel, or ischemic symptoms, and an in-lesion diameter stenosis ≥50% by QCA.
| participants | CYPHER® Stent |
|---|---|
| Rate of Clinically Driven Target Vessel Revascularization (TVR) | 124 |
Defined as target vessel revascularization, recurrent infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vessel.
| participants | CYPHER® Stent |
|---|---|
| Rate of Target Vessel Failure (TVF) | 184 |
MACE includes Death, myocardial infarction, emergent bypass surgery, or target lesion revascularization at 12 months
| participants | CYPHER® Stent |
|---|---|
| Rate of Major Adverse Cardiac Events (MACE) | 172 |
Protocol defined ST includes early and late ST. Early thrombosis is defined as composite thirty-day ischemic endpoint including death, Q-wave myocardial infarction, or subabrupt closure requiring revascularization. Late thrombosis is defined as myocardial infarction occurring \> 30 days after the index procedure and attributable to the target vessel with angiographic documentation (site reported or by qualitative coronary angiography) of thrombus or total occlusion at the target site and freedom from an interim revascularization of the target vessel.
| participants | CYPHER® Stent |
|---|---|
| Rate of Protocol Defined Stent Thrombosis (ST) | 21 |
ARC defined ST classifies ST by type - definite, probable, possible; by timing - acute, sub-acute, late, very late. Definite includes angiographic or pathologic confirmation; probable includes Any unexplained death within the first 30 days or Any MI (related to documented acute ischemia and without another obvious cause) in the territory of the stent; Possible includes Any unexplained death \> 30 days. Acute includes those ≤ 24 hours post procedure; sub-acute includes those \> 24 hours to ≤ 30 days post procedure; and late includes those \> 30 days to ≤ 1 year post procedure; and very late includes those \> 1 year post procedure.
| participants | CYPHER® Stent |
|---|---|
| Rate of Academic Research Consortium (ARC) Defined Stent Thrombosis (ST) | 26 |
Defined by the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) classification, including severe and moderate bleeding combined.
| participants | CYPHER® Stent |
|---|---|
| Rate of Protocol Defined Major Bleeding Complications | 71 |
Include all deaths due to cardiac causes.
| participants | CYPHER® Stent |
|---|---|
| Rate of Cardiac Death | 18 |
Include all deaths due to non-cardiac causes.
| participants | CYPHER® Stent |
|---|---|
| Rate of Non-cardiac Death | 16 |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CYPHER® Stent | — | 34/2,509 (1.4%) | 414/2,509 (16.5%) |
| Event | CYPHER® Stent |
|---|---|
| Cardiac DeathCardiac disorders | 18/2509 |
| Non-cardiac deathGeneral disorders | 16/2509 |
| Event | CYPHER® Stent |
|---|---|
| Angina pectorisCardiac disorders | 108/2509 |
| Coronary artery dissectionCardiac disorders | 79/2509 |
| Myocardial infarctionCardiac disorders | 76/2509 |
| Angina unstableCardiac disorders | 53/2509 |
| Coronary artery diseaseCardiac disorders | 43/2509 |
| Catheter site haematomaGeneral disorders | 39/2509 |
| Coronary artery occlusionCardiac disorders | 31/2509 |
| In-stent coronary artery restenosisInjury, poisoning and procedural complications | 28/2509 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 27/2509 |
| Cardiac enzymes increasedInvestigations | 26/2509 |
Enrolled subjects were those who signed the informed consent and had met all of the inclusion and none of the exclusion criteria, and the target lesion had been successfully crossed with the intracoronary guidewire which was positioned intraluminally in the distal vessel. Enrolled subjects were also Intent to Treat (ITT).
| Age, Categorical(Participants) | CYPHER® Stent |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 1368 |
| >=65 years | 1141 |
| Age, Continuous(years) | CYPHER® Stent |
|---|---|
| Mean | 63.26 ± 10.64 |
| Sex: Female, Male(Participants) | CYPHER® Stent |
|---|---|
| Female | 785 |
| Male | 1724 |
| Ethnicity (NIH/OMB)(Participants) | CYPHER® Stent |
|---|---|
| Hispanic or Latino | 132 |
| Not Hispanic or Latino | 2293 |
| Unknown or Not Reported | 84 |
| Race (NIH/OMB)(Participants) | CYPHER® Stent |
|---|---|
| American Indian or Alaska Native | 6 |
| Asian | 37 |
| Native Hawaiian or Other Pacific Islander | 6 |
| Black or African American | 185 |
| White | 2225 |
| More than one race | 0 |
| Unknown or Not Reported | 50 |
| Region of Enrollment(participants) | CYPHER® Stent |
|---|---|
| United States | 2509 |
The record gives a start of Aug 2009, a primary completion of Jan 2012 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2013, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Clopidogrel · Aspirin · Prasugrel